Premium
This is an archive article published on August 13, 2020

Covid-19: Expert group plans digital backend to track vaccine

Sources said a decision was also taken that the Centre would handle procurement of the vaccines. “States must desist from investing time and money into the procurement process. The high-powered committee will be doing it in a centralised manner,” a source said.

Coronavirus vaccine, UNICEF, vaccine quantities for COVID-19, Covid vaccines production, Drugmakers Covid vaccine, world newsCapacity is expected to reach 610 million doses by the end of this year, Zheng Zhongwei from the National Health Commission said. (Representational)

At its first meeting on Wednesday, the National Expert Group on vaccine administration for Covid-19 held detailed deliberations on modifying existing technology platforms to track potential vaccines from procurement to last-mile delivery.

Sources told The Indian Express that talks were held on building a digital infrastructure so that a potential vaccine, from the several being developed, can be administered to a large population. Specifically, sources said, there was a discussion on upgrading the existing eVIN (Electronic Vaccine Intelligence Network) — an indigenously developed technology that tracks vaccine stocks digitally.

Sources said a decision was also taken that the Centre would handle procurement of the vaccines. “States must desist from investing time and money into the procurement process. The high-powered committee will be doing it in a centralised manner,” a source said.

Story continues below this ad

READ | Gold plunges around 10% in 2 days amid profit-booking, hopes of COVID vaccine

About talks on building a digital platform for Covid-19 vaccines, the source said, “We may have facility-based administration of the vaccine or we may, in all probability, have a mechanism for administration of the vaccine at the sub-facility-level because the population to cover is big. Therefore, we need an IT system to track the vaccine from the stage it is procured, ensure temperature parameters are met in storage, as well as monitor cold chain requirements and transportation of the vaccine on a real-time basis.”

Work is already on to modify existing platforms, including e-VIN, used by the government to track vaccines. “This platform has to be built up,” the source said.

Another issue discussed at Wednesday’s meeting was positioning India as a global player on the vaccine front, by leveraging its vaccine manufacturing as well as research and development facilities. The idea was to project that “India could provide a vaccine not only to its own population but also to its key partners in the neighbourhood, and to low and middle-income group countries”, the source said. “We will engage with all important international players, the WHO, GAVI (an international alliance for vaccines against infectious diseases), etc.”

Story continues below this ad

Bonus Reading | When the Russia vaccine can be available and if it will come to India 

The meeting also discussed “financial projections” on procurement of Covid-19 vaccines. However, the talks were preliminary, the source said, given that certain vaccines are double-dose vaccines and some single-dose, and that there are multiple vaccine candidates right now.

In a statement, the government said the meeting had discussed issues related to vaccine safety and surveillance, and measures to ensure equitable and transparent delivery and to involve the community in creating awareness once a vaccine is available.

The Indian Express had reported earlier that the National Expert Group would also look at mechanisms to track specific high-risk groups such as healthcare workers, the elderly and individuals with comorbidites, who are likely to be the first to be administered the vaccines.

Story continues below this ad

Wednesday’s meeting was chaired by Dr V K Paul, Member, NITI Aayog, with Rajesh Bhushan, Secretary, Ministry of Health and Family Welfare (MoHFW), as co-chair. Others present included top scientists from outside the government, specialists from premier government research institutes, and Secretaries of Commerce, Finance and External Affairs Ministries.

Kaunain Sheriff M is an award-winning investigative journalist and the National Health Editor at The Indian Express. He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, an investigation into one of the world’s most powerful pharmaceutical companies. With over a decade of experience, Kaunain brings deep expertise in three areas of investigative journalism: law, health, and data. He currently leads The Indian Express newsroom’s in-depth coverage of health. His work has earned some of the most prestigious honours in journalism, including the Ramnath Goenka Award for Excellence in Journalism, the Society of Publishers in Asia (SOPA) Award, and the Mumbai Press Club’s Red Ink Award. Kaunain has also collaborated on major global investigations. He was part of the Implant Files project with the International Consortium of Investigative Journalists (ICIJ), which exposed malpractices in the medical device industry across the world. He also contributed to an international investigation that uncovered how a Chinese big-data firm was monitoring thousands of prominent Indian individuals and institutions in real time. Over the years, he has reported on several high-profile criminal trials, including the Hashimpura massacre, the 2G spectrum scam, and the coal block allocation case. Within The Indian Express, he has been honoured three times with the Indian Express Excellence Award for his investigations—on the anti-Sikh riots, the Vyapam exam scam, and the abuse of the National Security Act in Uttar Pradesh. ... Read More

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement